Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
Year: 2020
Type: article
Abstract: Achievement of complete response (CR) in multiple myeloma (MM) has been defined by the International Myeloma Working Group (IMWG) as concurrent demonstration of disappearance of monoclonal protein in the serum and urine with negative immunofixation (IFE), in addition to a bone marrow biopsy demonstrating < 5% bone marrow plasma cells (BMPC) 1 , 2 . With advancements in myeloma-directed therapies and increasing CR rates, it is imperative that accurate and uniform application of CR criteria be utilized, especially with increased incorporation of minimal residual disease assessment 3 , 4 . While obtaining serum and urine samples for monoclonal protein analyses are simple, bone marrow biopsies are associated with pain, are inconvenient, and are burdensome to patients.
Source: Blood Cancer Journal
Authors: Marcella A. Tschautscher, Dragan Jevremovic, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Prashant Kapoor, David Dingli, Lisa Hwa, Amie Fonder, Miriam Hobbs, Suzanne Hayman, John Lust, Stephen J. Russell, Nelson Leung, Ronald S. Go, Yi Lin, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,580
Funders: Mayo Clinic, National Cancer Institute
Award: G1016754749
OpenAlex ID: W3089368137